Bestatin as an Experimental Tool in Mammals

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|2|1|67-85

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.2, Iss.1, 2001-03, pp. : 67-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progress in the Development of Bestatin Analogues as Aminopeptidases Inhibitors

By  

Current Medicinal Chemistry, Vol. 18, Iss. 7, 2011-03 ,pp. : 964-976

Bentham Science Publishers

Access to resources Recommend Favorite

An additional Japanese marketing application for ubenimex [Bestatin] has been withdrawn

By  

Inpharma, Vol. 1, Iss. 1428, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

LYP3, a New Bestatin Derivative for Aminopeptidase N Inhibition

By  

Medicinal Chemistry, Vol. 7, Iss. 1, 2011-01 ,pp. : 32-36

Bentham Science Publishers

Access to resources Recommend Favorite

The Synthesis and Activity Evaluation of a Bestatin Derivative (LYP) as an Aminopeptidase N Inhibitor

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 6, 2009-09 ,pp. : 420-423

Bentham Science Publishers

Access to resources Recommend Favorite

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

By Gao Jian-Jun  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 574-582

Springer Publishing Company

Access to resources Recommend Favorite